Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors

Molecular Cancer Therapeutics

Volumn 5, Issue 4, 2006, Pages 1007-1013

  Guo, Jun ^a   Marcotte, Patrick A ^a   McCall, J Owen ^a   Dai, Yujia ^a   Pease, Lori J ^a   Michaelides, Michael R ^a   Davidsen, Steven K ^a   Glaser, Keith B ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 5 FLUORO 3 [6 (4 METHYL 1 PIPERAZINYL) 1H BENZIMIDAZOL 2 YL] 2(1H) QUINOLINONE; 6 [2 (METHYLCARBAMOYL)PHENYLSULFANYL] 3 E [2 (PYRIDIN 2 YL)ETHENYL]INDAZOLE; ABT 869; ANTINEOPLASTIC AGENT; AXITINIB; CHIR 258; COLONY STIMULATING FACTOR RECEPTOR; IMATINIB; N [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] N' (2 FLUORO 5 METHYLPHENYL)UREA; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; IC 50; INHIBITION KINETICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

3T3 CELLS; ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; ENZYME INHIBITORS; HUMANS; INDAZOLES; KINETICS; LEAD; MICE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 33646559845     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0359     Document Type: Article

References (27)

1. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95:1276-99.
2. Weinberg RA. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 1989;49:3713-21.
3. Xie B, Tsao SW, Wong YC. Sex hormone-induced mammary carcinogenesis in female Noble rats: expression of TGF-beta-1 and its receptors, TGF-alpha, and EGF-R in mammary carcinogenesis. Breast Cancer Res Treat 1999;58:227-39.
4. Dickson C, Creer A, Fantl V. Mammary gland oncogenes as indicators of pathways important in mammary gland development. Oncogene 2000;19:1097-101.
5. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
6. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-40.
7. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992;13:265-70.
8. Ingber DE, Folkman J. How does extracellular matrix control capillary morphogenesis? Cell 1989;58:803-5.
9. Conway JG, McDonald B, Parham J, et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A 2005;102:16078-83.
10. Luo FR, Camuso A, McGlinchey K, et al. Evaluation of anti-osteoclastic activity of the novel, oral multi-targeted kinase inhibitor dasatinib (BMS-354825) [abstract B178]. Clin Cancer Res Suppl 2005;11:173.
11. Ide H, Seligson DB, Memarzadeh S, et al. Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc Natl Acad Sci U S A 2002;99:14404-9.
12. Aharinejad S, Paulus P, Sioud M, et al. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 2004;64:5378-84.
13. Kacinski BM. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med 1995;27:79-85.
14. Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869, a multi-targeted receptor tyrosine kinase inhibitor [abstract 676]. Proc Am Assoc Cancer Res 2005;46:1078.
15. Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006;5:995-1006.
16. Freddo J, Hu-Lowe D, Pithavala YK, Steinfeldt H. Dosage forms and methods of treatment using VEGFR inhibitors, United States Patent Application Publication No. US 2004/0224988, Agouron Pharmaceuticals, Inc.
17. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
18. Lee SH, Lopes de Menezes D, Vora J, et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005;11:3633-41.
19. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003;46:1116-9.
20. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
21. Kolb AJ, Kaplita PV, Hayes DJ, et al. Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence. Drug Discov Today 1998;2:333-42.
22. Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 2004;104:1931-9.
23. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.
24. Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005;105:3127-32.
25. Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia 2003;17:1713-21.
26. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52.
27. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors. Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.